Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
28/08/2026 16:30
BRIEF-China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million Aug 28 (Reuters) - China Biotech Services Holdings Ltd 8037.HK:
REVENUE FROM CONTINUING OPERATIONS FOR SIX MONTHS ENDED JUNE 30, 2026 HK$37.23 MILLION
BOARD HAS RESOLVED NOT TO DECLARE ANY DIVIDEND FOR PERIOD ENDED 30 JUNE 2026
HY PROFIT ATTRIBUTABLE HK$18.2 MILLION
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)